Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Herceptin approved in Canada for breast cancer therapy

Aug. 30, 1999

Berlex acquires marketing rights to Campath

Aug. 25, 1999

Chiron files long-term survival data for Proleukin with the FDA

Aug. 23, 1999

Clinical trials of SRL-172 in lung cancer are progressing

Aug. 20, 1999

Biomira's BLP25 cancer vaccine tested at higher dose and frequency

Aug. 17, 1999

CEA-Cide granted orphan drug status for ovarian cancer

Aug. 13, 1999

Vaccination with HPV16 peptides in advanced cervical carcinoma

Aug. 6, 1999

Phase I trial begins for SMART 1D10 antibody in non-Hodgkin's B-cell lymphoma

Aug. 5, 1999

Herceptin approved and launched in Switzerland

Aug. 4, 1999

Second U.S. patent covers GVAX cancer vaccine technology; positive lung cancer results reported

July 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026